Valeant Pharmaceuticals International, Inc. – Company Overview
|Company||Valeant Pharmaceuticals International, Inc.|
|Headquarters||2150 St. Elzéar Blvd., West Laval, Quebec, Canada|
|CEO||Joseph C. Papa|
|CFO||Robert L. Rosiello|
|NYSE stock symbol||VRX|
|Revenue||$10,446.5 millions USD (2015)|
|Operating income||$1,527.4 millions USD (2015)|
|Net loss||$(287.8) millions USD (2015)|
|IR contact number||(949) 461 6002|
|IR email address||[email protected]|
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) is a multinational pharmaceutical and medical devices company, listed on the New York Stock Exchange, and based in Laval, Québec, Canada.
The company has a broad portfolio of generic and branded pharmaceuticals, over-the-counter (“OTC”) products, and medical devices (such as aesthetics devices and ophthalmic surgical equipment).
It has a team of approximately 16,000 employees, with manufacturing sites in Canada, Brazil, Poland and Mexico.
Valeant Pharmaceuticals markets its products directly or indirectly in over 100 countries. In its Developed Markets segment Valeant focuses on eye health, dermatology, and neurology therapeutic classes. In its Emerging Markets segment the company primarily focuses on OTC products, medical devices, and branded generics.
It has a portfolio of approximately 1,500 products, in addition to a number of different drugs in late-stage clinical trials.
Its principal pharmaceutical products include Wellbutrin XL® (a formulation of bupropion for the treatment of major depressive disorder), Zovirax® Cream and Zovirax® Ointment (topical antivirals against herpes viruses), and Arestin® (a subgingival sustained-release antibiotic).
Valeant has chosen to expand through mergers and acquisitions, rather than investing in research and development. While some analysts have criticized this path, others say it is the only way to grow rapidly.
Valeant Pharmaceuticals International, Inc. – Financial Results
|Key Figures (in millions of USD)||2015*||2014*|
|Operating income (loss)||$1,527.4||$2,000.7|
|Net income (loss)||$(287.8)||$879.4|
|Cash and cash equivalents, beginning of year||$322.6||$600.3|
|Cash and cash equivalents, end of year||$597.3||$322.6|
*Year Ended December 31, 2015 and 2014
Source: “Valeant Pharmaceuticals International, Inc. – 2015 FORM 10-K”
News about Valeant Pharmaceuticals International, Inc. reported by our Market Business News team
January 2, 2016: Bill Ackman’s hedge fund just sold 5 million shares in Valeant